FAZACLO ODT (clozapine) by Jazz Pharmaceuticals is unknown. First approved in 2004.
Drug data last refreshed 5h ago · AI intelligence enriched 1mo ago
FAZACLO ODT is an orally disintegrating tablet formulation of clozapine, a second-generation antipsychotic approved in 2004 for treatment-resistant schizophrenia. The drug works primarily through antagonism of dopamine D2 and serotonin 5-HT2A receptors, with additional activity at adrenergic, cholinergic, and histaminergic receptors. Clozapine remains one of the most efficacious antipsychotics for severe, treatment-resistant psychotic disorders.
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), signaling potential team restructuring and shift toward managed care and market access roles.
unknown. However, it has been proposed that the therapeutic efficacy of clozapine in schizophrenia is mediated through antagonism of the dopamine type 2 (D 2 ) and the serotonin type 2A (5-HT 2A ) receptors. Clozapine also acts as an antagonist at adrenergic, cholinergic, histaminergic and other…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia
Biomarkers in Clozapine-responding Schizophrenia
An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults
Augmenting Clozapine With Sertindole - SERCLOZ
Randomized Evaluation of the Effectiveness of Clozapine and Aripiprazole Versus Clozapine and Haloperidol in the Treatment of Schizophrenia
Worked on FAZACLO ODT at Jazz Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
FAZACLO ODT roles are concentrated in commercial and market access functions as the product approaches loss of exclusivity. Career growth on this product is limited by its LOE trajectory; opportunities exist in managed care negotiation, generic transition planning, and specialty pharmacy partnerships rather than expansion or launch activities.